HALOBETASOL PROPIONATE

Search structure
Trade Names:
Synonyms:
Status: Approved (1990)
Entry Type: Small molecule
Molecule Category: Salt Prodrug
UNII: 91A0K1TY3Z
Parent Compound:

Structure
InChI Key BDSYKGHYMJNPAB-LICBFIPMSA-N
Smile CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
InChI
InChI=1S/C25H31ClF2O5/c1-5-21(32)33-25(20(31)12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15-,16-,18-,19-,22-,23-,24-,25-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C25H31ClF2O5
Molecular Weight 484.97
AlogP 4.05
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 4.0
Polar Surface Area 80.67
Molecular species NEUTRAL
Aromatic Rings 0.0
Heavy Atoms 33.0

Pharmacology

Action Mechanism of Action Reference
AGONIST Glucocorticoid receptor agonist PubMed PubMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Psoriasis 4 D011565 ClinicalTrials
Dermatitis, Atopic 2 D003876 ClinicalTrials

Related Entries

Scaffolds

UNKNOWN
Mixture

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Injury, poisoning and procedural complications
28.97
General disorders and administration site conditions
27.1
Skin and subcutaneous tissue disorders
8.41
Immune system disorders
7.48
Nervous system disorders
6.54
Product issues
3.74
Cardiac disorders
2.8
Psychiatric disorders
2.8

Cross References

Resources Reference
ChEBI 135782
ChEMBL CHEMBL1200908
DrugCentral 1349
EPA CompTox DTXSID6046636
FDA SRS 91A0K1TY3Z
PubChem 6918178
SureChEMBL SCHEMBL33858
ZINC ZINC000003920028
CONTENTS